Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186238 · ClinicalTrials.gov registry record · Phase 2
High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
A Phase 2 study of Multiple Myeloma, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT00186238: Completed Phase 2 study of Multiple Myeloma, sponsored by Stanford University.
NCT00186238 is a Phase 2 study of Multiple Myeloma that has completed, run by Stanford University. The registered enrollment target is 300 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186238, a Phase 2 study of Multiple Myeloma, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the role of autologous hematopoietic cell rescue in the treatment of multiple myeloma.
Conditions Studied
Interventions
- PROCEDURE high dose chemotherapy then autologous hematopoietic cell transplant
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 1994-09 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00186238
The ClinicalTrials.gov registry entry for NCT00186238 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (45% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which high dose chemotherapy then autologous hematopoietic cell transplant is the first listed.
NCT00186238 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00186238 about?
NCT00186238 is a clinical study titled "High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma". To assess the role of autologous hematopoietic cell rescue in the treatment of multiple myeloma.
What is the current status of trial NCT00186238?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 1994-09. Estimated completion is 2010-04.
What conditions does trial NCT00186238 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00186238?
The interventions under investigation include: high dose chemotherapy then autologous hematopoietic cell transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00186238?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00186238 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.